Regeneron Pharmaceuticals

Regeneron Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
1988-01-01
Employees
13.4K
Market Cap
$132.4B
Website
http://www.regeneron.com
Introduction

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

First Posted Date
2021-10-18
Last Posted Date
2024-04-26
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
25
Registration Number
NCT05081388
Locations
🇺🇸

PNS Clinical Research, LLC, Mission Viejo, California, United States

🇺🇸

PharmaTex Research, LLC, Amarillo, Texas, United States

🇺🇸

Ark Clinical Research, Long Beach, California, United States

and more 16 locations

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2021-10-12
Last Posted Date
2023-07-24
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
66
Registration Number
NCT05074433
Locations
🇺🇸

Innovative Research of West Florida, Inc., Clearwater, Florida, United States

🇺🇸

Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois, United States

🇺🇸

Institute of Human Virology, Baltimore, Maryland, United States

and more 50 locations

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

First Posted Date
2021-10-07
Last Posted Date
2024-12-05
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
235
Registration Number
NCT05070858
Locations
🇺🇸

HonorHealth Neurology 2018, Scottsdale, Arizona, United States

🇺🇸

University of California Irvine, Irvine, California, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

and more 133 locations

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2021-08-05
Last Posted Date
2023-03-06
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
7
Registration Number
NCT04992273
Locations
🇺🇸

Advanced Research Center, Inc, Anaheim, California, United States

🇺🇸

Stony Brook University Hospital, Stony Brook, New York, United States

🇺🇸

SUNY Upstate Medical University, Syracuse, New York, United States

and more 4 locations

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2021-07-29
Last Posted Date
2024-12-09
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
237
Registration Number
NCT04982224
Locations
🇺🇸

University of California Irvine School of Medicine - Suite 400, Room 407, Orange, California, United States

🇺🇸

University of Colorado Hospital Anshutz Outpatient Pavillion, Denver, Colorado, United States

🇺🇸

Johns Hopkins Hospital - Clinical Study Location - Skip Viragh Outpatient Cancer Building, Baltimore, Maryland, United States

and more 9 locations

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

First Posted Date
2021-07-29
Last Posted Date
2024-06-11
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
446
Registration Number
NCT04981717
Locations
🇺🇸

Integrated Research of Inland, Inc, Riverside, California, United States

🇺🇸

Allergy and Asthma Specialists PSC, Owensboro, Kentucky, United States

🇺🇸

Allergy Partners of Western North Carolina, Asheville, North Carolina, United States

and more 89 locations

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Active, not recruiting
Conditions
First Posted Date
2021-07-13
Last Posted Date
2024-05-17
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
717
Registration Number
NCT04959448
Locations
🇺🇸

John Hopkins University School Of Medicine, Baltimore, Maryland, United States

🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

🇺🇸

The University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM, Chicago, Illinois, United States

and more 78 locations

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

First Posted Date
2021-06-07
Last Posted Date
2024-11-08
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
77
Registration Number
NCT04916002
Locations
🇺🇸

University of California, Los Angeles, California, United States

🇺🇸

Ohio State University, Columbus, Ohio, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 21 locations

Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

First Posted Date
2021-05-17
Last Posted Date
2023-06-13
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
6
Registration Number
NCT04888507
Locations
🇬🇧

Regeneron Study Site, Leeds, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath